Key Takeaways
- • NeueHealth completed its acquisition by New Enterprise Associates (NEA) and a consortium of investors at an enterprise value of $1.465 billion, representing a $165 million increase from the initial $1.3 billion price announced in January 2025.
- • Common stockholders will receive $7.33 per share in cash, with the company's stock ceasing NYSE trading on October 2, 2025. CEO Mike Mikan and the full executive leadership team are rolling over 100% of their equity interests into the newly private entity, signaling management confidence in the go-forward strategy.
- • NEA and 12 other existing investors have executed rollover agreements, converting their stakes into equity positions in the private company rather than taking cash proceeds, indicating sustained conviction in NeueHealth's value-based care technology platform.
- • A secondary tender offer valued at approximately $300 million for employees and early investors is scheduled to close in November 2025, led by Accel and GIC, providing liquidity for additional shareholder classes.
Summary
NeueHealth has officially transitioned to private ownership following the completion of its $1.465 billion acquisition by New Enterprise Associates and an affiliated investor consortium. The finalized deal closed on October 2, 2025, marking the delisting of the company's common stock from the New York Stock Exchange. The transaction represents a material upward repricing from the January 2025 announcement, which valued the enterprise at $1.3 billion—a $165 million increase reflecting market momentum and investor appetite for the healthcare technology sector's value-based care segment.
Under the acquisition terms, holders of NeueHealth common stock will receive $7.33 per share in cash consideration. The structure incorporates meaningful equity rollover commitments from key stakeholders, demonstrating alignment between public shareholders, management, and controlling investors. NEA and 12 co-investors have elected to exchange their equity stakes for ownership positions in the now-private entity rather than liquidating for cash, a decision that typically signals confidence in management execution and near-term value creation under private control.
NeueHealth's executive leadership, led by President and CEO Mike Mikan, has committed 100% of their equity interests to rollover arrangements, signaling unified management backing for the company's strategic direction. Mikan stated that the transaction enables the organization to "advance our value-driven, consumer-centric care model and drive long-term, sustainable growth," emphasizing the operational flexibility that private ownership may provide relative to public market pressures. The company's core mission of aligning provider, payer, and consumer interests through technology-enabled value-based care delivery remains intact post-transaction.
A secondary tender offer valued at approximately $300 million is scheduled to close in November 2025, providing additional liquidity for employees and early-stage investors. The secondary round is being led by Accel and GIC, signaling fresh capital infusion and potential validation from prominent growth-stage investors. This transaction structure—combining a primary acquisition with a contemporaneous employee and early-investor secondary—is common in healthcare technology take-privates, balancing founder/early-backer liquidity with management retention through rollover equity commitments.
Under the acquisition terms, holders of NeueHealth common stock will receive $7.33 per share in cash consideration. The structure incorporates meaningful equity rollover commitments from key stakeholders, demonstrating alignment between public shareholders, management, and controlling investors. NEA and 12 co-investors have elected to exchange their equity stakes for ownership positions in the now-private entity rather than liquidating for cash, a decision that typically signals confidence in management execution and near-term value creation under private control.
NeueHealth's executive leadership, led by President and CEO Mike Mikan, has committed 100% of their equity interests to rollover arrangements, signaling unified management backing for the company's strategic direction. Mikan stated that the transaction enables the organization to "advance our value-driven, consumer-centric care model and drive long-term, sustainable growth," emphasizing the operational flexibility that private ownership may provide relative to public market pressures. The company's core mission of aligning provider, payer, and consumer interests through technology-enabled value-based care delivery remains intact post-transaction.
A secondary tender offer valued at approximately $300 million is scheduled to close in November 2025, providing additional liquidity for employees and early-stage investors. The secondary round is being led by Accel and GIC, signaling fresh capital infusion and potential validation from prominent growth-stage investors. This transaction structure—combining a primary acquisition with a contemporaneous employee and early-investor secondary—is common in healthcare technology take-privates, balancing founder/early-backer liquidity with management retention through rollover equity commitments.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.